Literature DB >> 16007640

Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.

Anjali Saqi1, Shine S Yun, Gordon H Yu, Diane Alexis, Robert N Taub, Charles A Powell, Alain C Borczuk.   

Abstract

CD138 (Syndecan-1) is a transmembrane heparan sulfate proteoglycan present on the surface of plasma cells and epithelial cells. CD138 is also expressed in some hematopoietic neoplasms and has recently been observed in carcinomas. We characterized CD138 expression in cell-block preparations of fluids/effusions, focusing on the distinction between carcinoma and mesothelioma. One hundred formalin-fixed, paraffin-embedded cell-block sections of fluids/effusions consisting of 58 metastatic carcinomas, 24 mesotheliomas, 11 reactive mesothelial cell proliferations, 3 lymphomas, 3 metastatic sarcomas, and 1 metastatic melanoma were stained with a monoclonal antibody against CD138. CD138 staining was observed in 32/58 (55%) metastatic carcinomas and 2/24 (8%) mesotheliomas; all reactive mesothelial cells, lymphomas, sarcomas, and melanoma were negative. CD138 is a highly specific marker in the differential diagnosis of carcinoma vs. mesothelioma. Distinct membranous staining without background staining of most inflammatory cells makes CD138 an ideal marker for cell-block preparations of fluids/effusions. It should be an integral component of the epithelial-mesothelial antibody panel. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007640     DOI: 10.1002/dc.20297

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  9 in total

1.  Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2.

Authors:  Bálint Péterfia; Tibor Füle; Kornélia Baghy; Krisztina Szabadkai; Alexandra Fullár; Katalin Dobos; Fang Zong; Katalin Dobra; Péter Hollósi; András Jeney; Sándor Paku; Ilona Kovalszky
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

Review 2.  Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication.

Authors:  Tünde Szatmári; Rita Ötvös; Anders Hjerpe; Katalin Dobra
Journal:  Dis Markers       Date:  2015-09-01       Impact factor: 3.434

3.  Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.

Authors:  Filip Mundt; Gustav Nilsonne; Sertaç Arslan; Karola Csürös; Gunnar Hillerdal; Huseyin Yildirim; Muzaffer Metintas; Katalin Dobra; Anders Hjerpe
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

Review 4.  The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors.

Authors:  Tünde Szatmári; Katalin Dobra
Journal:  Front Oncol       Date:  2013-12-19       Impact factor: 6.244

5.  Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.

Authors:  Filip Mundt; Ghazal Heidari-Hamedani; Gustav Nilsonne; Muzaffer Metintas; Anders Hjerpe; Katalin Dobra
Journal:  Biomed Res Int       Date:  2014-07-24       Impact factor: 3.411

6.  Rare Breast Carcinoma with Paradoxical Plasma Cell Immunoprofile: A Case Report.

Authors:  Eugen Sebastian Grădinaru; Mihai-Ciprian Stoicea; Liliana Mocanu; Iulian Antoniac; Daniela Gheorghiță; Alina Gabriela Mihaela Grigore
Journal:  Medicina (Kaunas)       Date:  2020-02-05       Impact factor: 2.430

Review 7.  Heterogeneity and Functions of Tumor-Infiltrating Antibody Secreting Cells: Lessons from Breast, Ovarian, and Other Solid Cancers.

Authors:  Yasmine Lounici; Olivia Le Saux; Gabriel Chemin; Pauline Wajda; Sarah Barrin; Justine Berthet; Christophe Caux; Bertrand Dubois
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

Review 8.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

9.  Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues.

Authors:  Simon Kind; Christina Merenkow; Franziska Büscheck; Katharina Möller; David Dum; Viktoria Chirico; Andreas M Luebke; Doris Höflmayer; Andrea Hinsch; Frank Jacobsen; Cosima Göbel; Sören Weidemann; Christoph Fraune; Christina Möller-Koop; Claudia Hube-Magg; Till S Clauditz; Ronald Simon; Guido Sauter; Waldemar Wilczak; Ahmed Abdulwahab Bawahab; Jakob R Izbicki; Daniel Perez; Andreas Marx
Journal:  Dis Markers       Date:  2019-12-23       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.